1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AZ And Boehringer Move Into Phase III With Rival Next-Gen CKD Drugs

 
• By Andrew McConaghie

Boehringer Ingelheim and AstraZeneca are once again going up against each other in chronic kidney disease, with Phase II results for their rival new agents showing promise. Unfortunately, they both also lie in the path of Novo Nordisk’s cardiometabolic juggernaut, Ozempic.

Kidney
Chronic kidney disease is estimated to affect around 850 million people worldwide • Source: Shutterstock

Boehringer Ingelheim and AstraZeneca’s SGLT2 inhibitor rivalry is stepping up as they look to expand the reach of their respective drugs in chronic kidney disease via combinations with new agents.

Both firms have just presented Phase II data for their new candidates: AstraZeneca for zibotentan, its novel oral high selective ETA receptor antagonist, and Boehringer for its selective aldosterone synthase inhibitor, BI 690517, both featuring at

Key Takeaways

  • Boehringer Ingelheim and Lilly’s Jardiance is the market leading SGLT2 inhibitor, but AZ is looking to close the gap as the products mature

  • The companies have just unveiled Phase II data from new agents aimed at improving outcomes in CKD when combined with an SGLT2 inhibitor

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.